Ceftazidime and cefamandole in the treatment of pneumonia.
Fifty-nine community-acquired pneumonias were treated in a randomized double blind trial with cefamandole or ceftazidime. A prospective scoring system was used to define severity. This made use of basic clinical data, associated diseases, white blood count, blood gases and chest radiographs. There were no serious side-effects from the drugs. There were two deaths and six failed treatment. The scoring system which defined an 'ill group' showed as good a response of these ill patients to the new cephalosporin, ceftazidime as to cefamandole.
D000328:Adult; D002435:Cefamandole / Q000009:adverse effects / Q000627:therapeutic use; D002442:Ceftazidime; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007275:Injections, Intravenous / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010689:Phlebitis / Q000209:etiology; D011014:Pneumonia / Q000188:drug therapy*; D011897:Random Allocation
D002511:Cephalosporins; D002435:Cefamandole; D002442:Ceftazidime